Free tool
FAERS Monitor: Lanreotide Acetate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215395 or its brand name (Lanreotide Acetate, Lanreotide Acetate). Reports on generic versions are filed under their own applications.
Reports
3,387
Serious
3,167
94% of reports
Hospitalization
1,126
Death reported
1,185
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,038
- off label use943
- diarrhoea596
- fatigue454
- abdominal pain347
- nausea328
- malignant neoplasm progression327
- weight decreased281
- malaise270
- asthenia269
- dizziness237
- vomiting234
- headache214
- decreased appetite204
- product dose omission issue194
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 29 |
| 2019 | 41 |
| 2020 | 58 |
| 2021 | 198 |
| 2022 | 338 |
| 2023 | 868 |
| 2024 | 666 |
| 2025 | 753 |
| 2026 | 413 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,772 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 327 | 19.9 | 17.9 | 5,857 |
| abdominal painSignal | 347 | 9.3 | 8.4 | 2,578 |
| deathSignal | 1,038 | 7.5 | 7.1 | 6,072 |
| off label useSignal | 943 | 6.7 | 6.3 | 4,754 |
| weight decreasedSignal | 281 | 6.3 | 5.6 | 1,251 |
| diarrhoeaSignal | 596 | 5.7 | 5.3 | 2,398 |
| decreased appetiteSignal | 204 | 5.5 | 4.8 | 746 |
| astheniaSignal | 269 | 4.4 | 4.0 | 727 |
| product dose omission issueSignal | 194 | 4.1 | 3.6 | 458 |
| malaiseSignal | 270 | 3.8 | 3.4 | 572 |
| fatigueSignal | 454 | 3.6 | 3.3 | 892 |
| vomitingSignal | 234 | 3.1 | 2.7 | 336 |
| dizzinessSignal | 237 | 3.0 | 2.6 | 311 |
| nauseaSignal | 328 | 2.6 | 2.3 | 326 |
| headacheSignal | 214 | 2.1 | 1.9 | 129 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.